AR117952A2 - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso - Google Patents
Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su usoInfo
- Publication number
- AR117952A2 AR117952A2 ARP190102386A ARP190102386A AR117952A2 AR 117952 A2 AR117952 A2 AR 117952A2 AR P190102386 A ARP190102386 A AR P190102386A AR P190102386 A ARP190102386 A AR P190102386A AR 117952 A2 AR117952 A2 AR 117952A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- treat
- cognitive disorders
- prevent cognitive
- humanized antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona métodos para usar y composiciones de anticuerpos humanizados que se unen a la proteína tau que está fosforilada en la serina en la posición 413. Reivindicación 1: Un anticuerpo pSer413 anti-tau que comprende: a) un dominio variable pesado seleccionado de SEQ ID Nº 116 y SEQ ID Nº 117; y b) un dominio variable liviano seleccionado de SEQ ID Nº 114, SEQ ID Nº 104, SEQ ID Nº 105, SEQ ID Nº 106, SEQ ID Nº 107, SEQ ID Nº 108, SEQ ID Nº 109, SEQ ID Nº 110, SEQ ID Nº 111, SEQ ID Nº 112, SEQ ID Nº 113 y SEQ ID Nº 103.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017035594A JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117952A2 true AR117952A2 (es) | 2021-09-08 |
Family
ID=62025891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100454A AR110875A1 (es) | 2017-02-27 | 2018-02-27 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso |
| ARP190102386A AR117952A2 (es) | 2017-02-27 | 2019-08-22 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100454A AR110875A1 (es) | 2017-02-27 | 2018-02-27 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10556950B2 (es) |
| EP (1) | EP3585810B1 (es) |
| JP (4) | JP2018139530A (es) |
| KR (1) | KR102701634B1 (es) |
| CN (2) | CN110382528A (es) |
| AR (2) | AR110875A1 (es) |
| AU (1) | AU2018224390C1 (es) |
| BR (1) | BR112019016490A2 (es) |
| CA (1) | CA3052538A1 (es) |
| CL (3) | CL2019002296A1 (es) |
| CO (1) | CO2019008786A2 (es) |
| CR (1) | CR20190363A (es) |
| DO (1) | DOP2019000215A (es) |
| EA (1) | EA201991726A1 (es) |
| GE (1) | GEP20227392B (es) |
| IL (1) | IL267945B2 (es) |
| JO (1) | JOP20180014A1 (es) |
| MA (1) | MA47608A (es) |
| MX (2) | MX2019009945A (es) |
| MY (1) | MY193821A (es) |
| NI (1) | NI201900086A (es) |
| PE (2) | PE20241514A1 (es) |
| PH (1) | PH12019501929A1 (es) |
| SG (2) | SG10201913419TA (es) |
| TW (2) | TWI848904B (es) |
| WO (2) | WO2018154392A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013180238A1 (ja) * | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| US20210355199A1 (en) | 2018-06-28 | 2021-11-18 | University Of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling |
| US12365724B2 (en) * | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| US20220381790A1 (en) | 2019-02-11 | 2022-12-01 | University Of Virginia Patent Foundation | Selection and blockade of fertilization competent male and female gametes |
| AU2020234718A1 (en) | 2019-03-13 | 2023-05-18 | Tearsolutions, Inc. | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| EP4007773A1 (en) * | 2019-08-06 | 2022-06-08 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| WO2021246413A1 (ja) * | 2020-06-02 | 2021-12-09 | 帝人ファーマ株式会社 | 抗ｉｇｆ－１受容体ヒト化抗体 |
| WO2021262791A1 (en) * | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN115322255B (zh) * | 2022-04-25 | 2025-03-07 | 上海药明生物医药有限公司 | 一种优化的Fc变体及其应用 |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| JP4754352B2 (ja) | 2003-08-29 | 2011-08-24 | 株式会社リバース・プロテオミクス研究所 | タンパク質の固定化方法 |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| RU2603078C2 (ru) | 2010-10-07 | 2016-11-20 | Ац Иммуне С.А. | Фармацевтическая композиция |
| TR201812636T4 (tr) * | 2010-10-11 | 2018-09-21 | Biogen Int Neuroscience Gmbh | İnsan anti-tau antikorları. |
| NZ626269A (en) | 2011-12-20 | 2016-06-24 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| WO2013180238A1 (ja) | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| EP3007726B1 (en) | 2013-06-10 | 2020-04-08 | Ipierian, Inc. | Methods of treating a tauopathy |
| ES2778498T3 (es) | 2013-12-20 | 2020-08-10 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| AR100978A1 (es) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2017
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en not_active Ceased
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
- 2018-02-27 IL IL267945A patent/IL267945B2/en unknown
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/en active Active
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en not_active Ceased
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
-
2019
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
-
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117952A2 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso | |
| CL2019003114A1 (es) | Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063) | |
| ECSP21025707A (es) | Anticuerpos estabilizadores de trem2 | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| CL2019001411A1 (es) | Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817) | |
| CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX2024011869A (es) | Anticuerpos anti-tau y metodos de uso | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| MX2022000112A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
| MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| CL2023003695A1 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso | |
| MX2020009465A (es) | Anticuerpos anti-klk5 y metodos de uso. | |
| EA202192101A1 (ru) | Соединения и их применение | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| MX2022006751A (es) | Minitrampas de vegf y metodos de uso de las mismas. | |
| BR112018071586A2 (pt) | uso de beta-agonistas da tireoide | |
| MX393805B (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| CR20220122A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares |